FDA Approves Juluca, a Novel 2-Drug Regimen for HIV-1 Infection In November, the U.S. Food and Drug Administration (FDA) approved ViiV Healthcare’s Juluca (dolutegravir and rilpivirine), a single-tablet, two-drug regimen of dolutegravir…Original Article
You may also like
Ariane de Ganck
Jasper Therapeutics merges with Kira Pharmaceuticals
Lilly to acquire AtaiBeckley in deal worth $2.8bn
Camena Bioscience appoints Gregory McGuinness as CEO
New €25 Million BioReliance Testing Facility Opens...
StockWatch: Lilly’s Up-to-$3.8B Deal for AtaiBeckley...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.
